These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31712933)

  • 21. [Transfusions and iron chelation in myelodysplastic syndromes].
    Pascal L
    Bull Cancer; 2023 Nov; 110(11):1176-1182. PubMed ID: 37543453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
    Steensma DP
    Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
    Pullarkat V
    Blood; 2009 Dec; 114(26):5251-5. PubMed ID: 19710499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2010 Nov; (11):CD007461. PubMed ID: 21069694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA
    Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron chelation therapy in patients with low- to intermediate-risk myelodysplastic syndrome: A systematic review and meta-analysis.
    Yang S; Zhang MC; Leong R; Mbuagbaw L; Crowther M; Li A
    Br J Haematol; 2022 Apr; 197(1):e9-e11. PubMed ID: 34927248
    [No Abstract]   [Full Text] [Related]  

  • 30. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
    Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron overload in myelodysplastic syndromes.
    Mahesh S; Ginzburg Y; Verma A
    Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes.
    Rozema J; van Asten I; Kwant B; Kibbelaar RE; Veeger NJGM; de Wit H; van Roon EN; Hoogendoorn M;
    Eur J Haematol; 2022 Dec; 109(6):772-778. PubMed ID: 36130872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myelodysplastic syndromes and the role of iron overload.
    Harvey RD
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
    Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
    Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron overload in patients with myelodysplastic syndromes.
    Jensen PD
    Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.